Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

ain. The Company has previously completed three Phase 3 studies in PHN, of which two met their primary endpoint. In those studies, a single, 60-minute treatment with NGX- 4010 applied directly to the site of pain reduced pain for up to 12 weeks. In addition to being studied in PHN, NGX-4010 was also studied in a successful Phase 3 clinical trial in painful HIV-DSP.

Regulatory and Commercialization Plans for NGX-4010

NeurogesX submitted an MAA, which was accepted by the EMEA under the centralized filing procedure in September 2007. The Company's MAA seeks approval in the European Union for a broad indication of peripheral neuropathic pain, which includes PHN, HIV-DSP and painful diabetic neuropathy (PDN), among others. The Company is evaluating strategies regarding its MAA that may include adding to the dossier the Company's second successful Phase 3 study in PHN and this most recent study in HIV-DSP to potentially support a broad label approval, or potentially a subset of indications. The Company expects to submit an NDA with the FDA in the second half of 2008 for PHN and will discuss with the agency the path forward for attaining approval for HIV- DSP.

NeurogesX has retained exclusive worldwide commercialization rights for NGX-4010 and intends to establish a focused specialty sales force in the United States to address its target market of pain centers and physicians. NeurogesX intends to enter into commercial partnerships for marketing and distribution outside the United States.

Conference Call and Webcast Information

A conference call to review the results of the C119 trial will begin at 5:00 p.m. EST (2:00 p.m. PST) on February 27, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, Jeffrey Tobias, Chief Medical Officer, and Stephen Ghiglieri, Chief Financial Officer.

The conference call dial-in numbers are 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up repla
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... 2014) The American Gastroenterological Association (AGA) Research ... Research Scholars. The AGA Research Scholar Awards program, ... independent and productive research careers in digestive diseases. ... an additional year allowing for three consecutive years ... junior faculty who are paving the way for ...
(Date:4/23/2014)... country as wealthy as the United States, it may come ... have access to adequate food due to lack of money ... Recent research at the University of Illinois using data from ... the seniors who are dealing with hunger are also facing ... percent of Americans over age 60 faced the threat of ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:More Americans in their golden years are going hungry 2
... Program and Its Impact on ... Meth Use in Montana, PALO ... the Finance Committee of the,United States Senate today. Siebel was invited to ... the state of Montana --,where the Meth Project implemented its first statewide ...
... WHITE PLAINS, N.Y., Sept. 18 Lynn Clark,Callister, ... Brigham Young,University, has joined the March of Dimes ... internationally recognized nursing leaders who,give direction and counsel ... "March of Dimes Nurse Advisory Council members represent ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... will present at the UBS Global Life,Sciences Conference at ... is being held at the Grand Hyatt in New ... investors through, http://www.viropharma.com and available through October 4, ...
... Suite operates with Gryphon compliance services ... in increased productivity for call centers, OKLAHOMA ... of,intelligent customer interaction solutions, today announced that it ... worldwide leader in,On-Demand Contact Governance solutions. This agreement ...
... Beginning Oct. 14, the,Appleton Museum of Art and ... personal mementos owned by Princess Diana. (Photo: ... of Wales: Dresses for a Cause," the exhibit,will ... by the princess,featuring 30 designer dresses. Event partnerships ...
... Inc. (OTCBB: PVCT) announced preliminary results of its Phase ... metastatic melanoma, the most aggressive form of skin cancer. ... effect on melanoma tumors in stage III patients. The ... total of 20 subjects at two sites in Australia. ...
Cached Medicine News:Health News:Meth Project Chairman Testifies Before U.S. Senate Finance Committee 2Health News:Meth Project Chairman Testifies Before U.S. Senate Finance Committee 3Health News:Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 3Health News:World's Largest Exhibit of Princess Diana's Dresses Hosted by Appleton Museum 2Health News:Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study 2
... designed for patient comfort as well as dependable ... at 5cm intervals and line marked each centimeter., ... available spanning most clinical needs and the range ... or two sensors., ,Flexilog single-use catheters are ...
... for 24-hour esophageal pH monitoring. , ... are reusable up to five times. ... same high quality materials as the ... available in many configurations., ,Contact ...
... VersaFlex™ disposable pH catheter is used ... worldwide for evaluating acid reflux events., ... esophageal pH monitoring. , ,Alpine's ... esophageal catheter on the market (4.7 ...
... single-use pH catheters are efficient, economical, ... allow greater patient comfort during the ... measurement systems have been designed to ... an accurate room-temperature calibration. The temperature ...
Medicine Products: